Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peppermint Oil vs Mebeverine in IBS (SLC6A4 Carriers)
NCT06914921Completed
- Sponsor
- S-LAB
- Start
- Feb 2024
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Randomised, double-blind trial (2 arms), sponsored by S-LAB. Primary endpoint: Irritable Bowel Syndrome Severity Scoring System at 12 weeks. Started Feb 2024; status: completed.
Beyond the preview
Go deeper on NCT06914921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914921.